Gilead Sciences, Inc. (NASDAQ:GILD) Receives $112.36 Average Price Target from Brokerages

Gilead Sciences, Inc. (NASDAQ:GILD) has been given an average rating of “Moderate Buy” by the twenty-six research firms that are covering the company, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold recommendation, fifteen have issued a buy recommendation and three have issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $112.36.

A number of research analysts recently issued reports on GILD shares. Morgan Stanley boosted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They set an “overweight” rating and a $125.00 price objective on the stock. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Friday, July 25th. Finally, Oppenheimer dropped their price target on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a research note on Friday, April 25th.

Gilead Sciences Price Performance

Shares of GILD opened at $114.76 on Monday. The firm has a market cap of $142.75 billion, a PE ratio of 24.16, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. Gilead Sciences has a 52-week low of $72.43 and a 52-week high of $119.96. The business’s 50 day moving average price is $110.29 and its two-hundred day moving average price is $106.39. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37.

Insiders Place Their Bets

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $113.94, for a total transaction of $1,139,400.00. Following the completion of the transaction, the chief executive officer owned 605,725 shares in the company, valued at approximately $69,016,306.50. This represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $277,575.00. Following the completion of the sale, the chief financial officer directly owned 162,610 shares in the company, valued at approximately $18,054,588.30. This represents a 1.51% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 82,000 shares of company stock valued at $8,984,175. 0.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its stake in shares of Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares in the last quarter. FMR LLC raised its holdings in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock valued at $3,724,306,000 after acquiring an additional 7,157,113 shares during the period. Nuveen LLC purchased a new stake in shares of Gilead Sciences during the first quarter worth $620,415,000. GAMMA Investing LLC boosted its holdings in shares of Gilead Sciences by 13,891.1% in the first quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company’s stock worth $285,761,000 after acquiring an additional 2,532,070 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Gilead Sciences by 19.7% in the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company’s stock worth $1,377,707,000 after acquiring an additional 2,458,954 shares during the period. Hedge funds and other institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.